99 citations,
July 2017 in “Clinical Reviews in Allergy & Immunology” New treatments for Alopecia Areata show promise but need to be more effective and affordable.
74 citations,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
47 citations,
October 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
44 citations,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
39 citations,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
32 citations,
December 2018 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
25 citations,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
23 citations,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
16 citations,
October 2020 in “Lipids in Health and Disease” Leptin affects skin and hair health and may worsen some skin conditions, but more research is needed to understand its full impact.
16 citations,
July 2020 in “International Journal of Molecular Sciences” Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
16 citations,
October 2018 in “Experimental Dermatology” Mesenchymal stem cell therapy may help treat alopecia areata by promoting hair growth and reducing inflammation.
15 citations,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
14 citations,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
November 2018 in “Journal of the American Academy of Dermatology” Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
9 citations,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
9 citations,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
6 citations,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
5 citations,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
5 citations,
July 2020 in “Curēus” Beard hair loss can signal early diabetes and thyroid issues, treatable with specific cream.
4 citations,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
4 citations,
April 2019 in “Cell Stem Cell” Certain immune cells in the skin can stop hair from growing.
3 citations,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.